Skip to main content

Advertisement

SpringerLink
Log in

Colorectal gastrointestinal stromal tumor

  • Published:
Techniques in Coloproctology Aims and scope Submit manuscript

Abstract

Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm arising in the digestive tract, with an estimated prevalence of 15–20 per 1,000,000. GISTs are related to the interstitial cells of Cajal and are characterized by constitutive over-expression of the transmembrane tyrosine kinase receptor KIT. This is produced by a patognomonic mutation of the proto-oncogene c-kit that occurs in up to 90% of cases. Exon 11 is affected most frequently; exons 9 and 13 are less commonly involved. One-third of GISTs lacking KIT mutations exhibits alternative activating mutations in the PDGFRα gene. Colorectal GISTs represent about 5–10% of the cases, mainly located in the rectum that is the third common site. Benign GISTs are more common, but many tumors are of uncertain malignant potential; tumor size and rate of mitosis are still the most reliable criteria for assessing the risk of an aggressive behavior. Surgery is the first-line treatment for resectable non-metastatic colorectal GIST. Standard oncologic resection is inappropriate because skip metastases and lymphatic spread are rarely reported. Segmental colectomy with negative margins is recommended, and local excision is oncologically adequate in highly selected rectal tumors. Radical surgery alone is not always curative especially in high-risk GISTs, and half of patients develops local recurrences or distant metastases after R0 operation. Medical therapeutic strategies have rapidly evolved after the introduction of targeted molecular therapy. Efficacy and safety of imatinib mesylate was first demonstrated in patients with metastatic and unresectable disease. Adjuvant and neoadjuvant use of imatinib are promising therapeutic options to improve the outcome of surgery to downstage unresectable lesions and to allow less extensive resections.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mazur MT, Clark HB (1983) Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 7:507–519

    Google Scholar 

  2. Kindblom LG, Remotti HE, Aldenborg F et al (1998) Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152:1259–1269

    CAS  PubMed  Google Scholar 

  3. Miettinen M, Sarlomo-Rikala M, Lasota J (1998) Gastrointestinal stromal tumor. Ann Chir Gynaecol 87:278–281

    CAS  PubMed  Google Scholar 

  4. Miettinen M, Sarlomo-Rikala M, Sobin LH, Lasota J (2000) Gastrointestinal stromal tumors and leiomyosarcomas in the colon: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases. Am J Surg Pathol 24:1339–1352

    Article  CAS  PubMed  Google Scholar 

  5. Chacon M, Roca E, Barugel M et al (2004) Report of solid cancer in patients with gastrointestinal stromal tumors (GIST). J Clin Oncol ASCO Annu Meet Proc (Post-Meeting Edition) 22:9065

    Google Scholar 

  6. Melis M, Choi EA, Anders R et al (2007) Synchronous colorectal adenocarcinoma and gastrointestinal stromal tumor (GIST). Int J Colorectal Dis 22:109–114

    Article  PubMed  Google Scholar 

  7. Welton ML, Varma MG, Amerhouser A. Colon, rectum and anus. In: Norton JA, Bollinger RR, Chang AE, Lowry SF, Mulvhill SJ, Pass HJ, Thompson RW (eds) Surgery: basic, science and clinical evidence. Springer, Berlin, pp 667–762

  8. Hirota S, Isozaki K, Moriyama Y et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577–580

    Article  CAS  PubMed  Google Scholar 

  9. Heinrich MC, Blanke CD, Druker BJ, Corless CL (2002) Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20:1692–1703

    Article  CAS  PubMed  Google Scholar 

  10. Lux ML, Rubin BP, Biase TL et al (2000) KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 156:791–1795

    CAS  PubMed  Google Scholar 

  11. Hirota S, Izoaki K, Moriyama Y et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumor. Science 279:577–580

    Article  CAS  PubMed  Google Scholar 

  12. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M (1998) CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific CD34. Mod Pathol 11:728–734

    CAS  PubMed  Google Scholar 

  13. Miettinen M, Kopczynski J, Makhlouf HR, Sarlomo-Rikala M, Gyorffy H, Burke A, Sobin LH, Lasota J (2003) Gastrointestinal stromal tumors, intramural leiomyomas and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical and moleculr genetic study of 167 cases. Am J Surg Pathol 27:625–641

    Article  PubMed  Google Scholar 

  14. Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M (1999) Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumor and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 154:53–60

    CAS  PubMed  Google Scholar 

  15. Connolly EM, Gaffney E, Reynolds JV (2003) Gastrointestinal stromal tumours. Br J Surg 90(10):1178–1186

    Article  CAS  PubMed  Google Scholar 

  16. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R et al (2001) KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61:8118–8121

    CAS  PubMed  Google Scholar 

  17. Lasota J, Wozniak A, Sarlomo-Rikala M, Rys J, Kordek R, Nassar A, Sobin LH, Miettinen M (2000) Mutations in exons 9 and 13 of KIT gene arerare events in gastrointestinal stromal tumors. A study of 200 cases. Am J Pathol 157:1091–1095

    CAS  PubMed  Google Scholar 

  18. Kinoshita K, Isozaki K, Hirota S, Nishida T, Chen H, Nakahara M et al (2003) C-kit mutation at exon 17 or 13 is very rare in sporadic gastrointestinal stromal tumors. J Gastroenterol Hepatol 18:147–151

    Article  CAS  PubMed  Google Scholar 

  19. Yantiss RK, Spiro IJ, Compton CC, Rosenberg AE (2000) Gastrointestinal stromal tumor versus intra-abdominal fibromatosis of the bowel wall: a clinically important differential diagnosis. Am J Surg Pathol 24:947–957

    Article  CAS  PubMed  Google Scholar 

  20. Medeiros F, Corless CL, Duensing A et al (2004) KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 28:889–894

    Article  PubMed  Google Scholar 

  21. Hassan I, Nancy You Y, Dozois EJ, Shayyan R, Smyrk TC, Okuno SH, Donohue J (2006) Clinical, pathologic and immunohistochemical characteristics of gastrointestinal stromal tumor of the colon and rectum: implications for surgical management and adjuvant therapies. Dis Colon Rectum 49(5):609–615

    Article  PubMed  Google Scholar 

  22. Changchien CR, Wu MC, Tasi WS et al (2004) Evaluation of prognosis for malignant rectal gastrointestinal stromal tumor by clinical parameters and immunohistochemical staining. Dis Colon Rectum 47:1922–1929

    Article  PubMed  Google Scholar 

  23. Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y, Kitamura Y (2003) Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 125:660–667

    Article  CAS  PubMed  Google Scholar 

  24. Miettinen M, Furlong M, Sarlomo-Rikala M et al (2001) Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am J Surg Pathol 25:1121–1133

    Article  CAS  PubMed  Google Scholar 

  25. Tworek JA, Goldblum JR, Weiss SW, Greenson JK, Appelman HD (1999) Stromal tumors of the abdominal colon: a clinicopathologic study of 20 cases. Am J Surg Pathol 23:937–945

    Article  CAS  PubMed  Google Scholar 

  26. Miettinen m, Lasota J (2003) Gastrointestinal stromal tumors (GITSs): definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol J Pathol 54:3–24

    PubMed  Google Scholar 

  27. Fletcher CD, Rubin BP, Biase TL, Chen CJ, Maclure T, Demetri G et al (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33:459–465

    Article  PubMed  Google Scholar 

  28. Langer C, Gunawan B, Schuler P et al (2003) Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumors. Br J Surg 90:332–339

    Article  CAS  PubMed  Google Scholar 

  29. DeMatteo RP, Lewis JJ, Leung D et al (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231:51–58

    Article  CAS  PubMed  Google Scholar 

  30. Aparicio T, Boige V, Sabourin JC et al (2004) Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours. Eur J Surg Oncol 30:1098–1103

    Article  CAS  PubMed  Google Scholar 

  31. Besana-Ciani I, Boni L, Dionigi G, Benevento A, Dionigi R (2003) Outcome and long term results of surgical resection for gastrointestinal stromal tumors (GIST). Scand J Surg 92:195–199

    CAS  PubMed  Google Scholar 

  32. Miettinen M, Sobin LH, Sarlomo-Rikala M (2000) Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol 13:1134–1142

    Article  CAS  PubMed  Google Scholar 

  33. Antonescu CR, Viale A, Sarran L et al (2004) Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res 10:3282–3290

    Article  CAS  PubMed  Google Scholar 

  34. Mudan SS, Conlon KC, Woodruff JM et al (2000) Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Cancer 88:66–74

    Article  CAS  PubMed  Google Scholar 

  35. Tran T, Davila JA, El-Serag HB (2005) The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1458 cases from 1992 to 2000. Am J Gastroenterol 100:162–168

    Article  PubMed  Google Scholar 

  36. Nilsson B, Bumming P, Meis-Kindblom JM, Oden A, Dortok A, Gustavsson B et al (2005) Gastrointestinal stromal tumors: the incidence, prevalence, clinical course and prognostication in the preimatinib mesylate era. Cancer 103:821–829

    Article  PubMed  Google Scholar 

  37. Pierie J, Choudry U, Muzikansky A et al (2001) The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 136:383–389

    Article  CAS  PubMed  Google Scholar 

  38. Roberts PJ, Eisenberg B (2002) Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer 38(Suppl 5):S37–S38

    Article  PubMed  Google Scholar 

  39. Baik SH, Kim NK, Lee KY, Sohn SK, Cho CH et al (2007) Gastrointestinal stromal tumor of the rectum: an analysis of seven cases. Surg Today 37:455–459

    Article  PubMed  Google Scholar 

  40. Gervaz P, Huber O, Bucher P, Sappino P, Morel P (2008) Trans-sacral (Kraske) approach for gastrointestinal stromal tumor of the lower rectum: old procedure for a new disease. Colorectal Dis 10:951–952

    CAS  PubMed  Google Scholar 

  41. Matsushima K, Kayo M (2007) Transsacral approach to resect a gastrointestinal stromal tumor in the rectum: report of two cases. Surg Today 37:698–701

    Article  PubMed  Google Scholar 

  42. Hellan M, Maker VK (2006) Transvaginal excision of a large rectal stromal tumor: an alternative. Am J Surg 191:121–123

    Article  PubMed  Google Scholar 

  43. Changchien CR, Wu MC, Tasi WS et al (2004) Evaluation of prognosis for malignant rectal gastrointestinal stromal tumor by clinical parameters and immunohistochemical staining. Dis Colon Rectum 47:1922–1929

    Article  PubMed  Google Scholar 

  44. Pidhorecky I, Cheney RT, Kraybill WG et al (2000) Gastrointestinal stromal tumors: current diagnosis, biologic behavior and management. Ann Surg Oncol 7:705–712

    Article  CAS  PubMed  Google Scholar 

  45. Joensu H, Roberts PJ, Sarlomo-Rikala M et al (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052–1056

    Article  Google Scholar 

  46. Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472–480

    Article  CAS  PubMed  Google Scholar 

  47. von Oosterom AT, Judson IR, Verweij J et al (2002) Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 38(Suppl 5):S83–S87

    Article  PubMed  Google Scholar 

  48. Verweij J, Casali PG, Zalcberg J et al (2004) Progression-free survival in gastrointestinal stromal tumours with high dose imatinib: randomised trial. Lancet 364:1127–1134

    Article  CAS  PubMed  Google Scholar 

  49. Verweij J, von Oosterom A, Blay JY et al (2003) Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 39:2006–2011

    Article  CAS  PubMed  Google Scholar 

  50. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H et al (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumors. J Clin Oncol 21:4342–4349

    Article  CAS  PubMed  Google Scholar 

  51. Haller F, Detken S, Schulten HJ, Happel N, Gunawan B, Kuhlgatz J et al (2007) Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumors (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. Ann Surg Oncol 14:526–532

    Article  PubMed  Google Scholar 

  52. Andtbacka RH, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PW et al (2007) Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 14:14–24

    Article  PubMed  Google Scholar 

  53. Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC, Watson JC et al (2008) Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 99:42–47

    Article  Google Scholar 

  54. Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D et al (2006) Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 24:2325–2331

    Article  CAS  PubMed  Google Scholar 

  55. Lo SS, Papachristou GI, Finkelstein SD et al (2005) Neoadjuvant imatinib in gastrointestinal stromal tumor of the rectum: report of a case. Dis Colon Rectum 48:1316–1319

    Article  PubMed  Google Scholar 

  56. Wassenberg N, Nunoo-Mensah JW, Beart RW Jr, Ker TS (2007) Is there a role for neoadjuvant treatment with Gleevec for large rectal gastrointestinal stromal tumor? Int J Colorectal Dis 22:981–982

    Article  Google Scholar 

  57. Van den Abbeele AD, Badawi RD (2002) Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 38(Suppl 5):S60–S65

    Google Scholar 

  58. Stroobants S, Goeminne J, Seegers M et al (2003) 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate. Eur J Cancer 39:2012–2020

    Article  CAS  PubMed  Google Scholar 

  59. Alberini JL, Al Nakib M, Wartski M, Gontier E, Cvitkovic F, Rixe O et al (2007) The role of PET scan in gastrointestinal stromal tumors. Gastroenterol Clin Biol 31:585–593

    Article  PubMed  Google Scholar 

  60. Gomes AL, Bardales RH, Milanezi F, Reis RM, Schmitt F (2007) Molecular analysis of c-kit and PDGFRA in GISTs diagnosed by EUS. Am J Clin Pathol 127:89–96

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The author declares that he has no conflict of interest related to the publication of this article.

Author information

Authors and Affiliations

  1. Department of Surgery, Unit of Coloproctology, Via Borea, 56, 18038, Sanremo, Italy

    A. Amato

Authors
  1. A. Amato
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Amato.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Amato, A. Colorectal gastrointestinal stromal tumor. Tech Coloproctol 14 (Suppl 1), 91–95 (2010). https://doi.org/10.1007/s10151-010-0631-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10151-010-0631-y

Keywords

Search

Navigation